Complement, Total, C3, and C4
General
Synonym/Acronym:
Total hemolytic complement, CH50, CH100.
Rationale
To detect inborn complement deficiency, evaluate immune diseases related to complement activity, and follow up on a patient’s response to therapy such as treatment for rheumatoid arthritis and systemic lupus erythematosus (SLE) in which complement is consumed at an increased rate.
Patient Preparation
There are no food, fluid, activity, or medication restrictions unless by medical direction.
Normal Findings
Method: Immunoturbidimetric for C3 and C4.
Complement Total (CH50) Units/mL | Method |
---|---|
39–90 | Immunoturbidimetry |
23–60 | Liposome Immunoassay |
60–140 | Enzyme Immunoassay |
100–300 | Quantitative Hemolysis (Classical method) |
Age | Conventional Units | SI Units (Conventional Units × 0.01) |
---|---|---|
Newborn | 57–116 mg/dL | 0.57–1.16 g/L |
6 mo–adult | 74–166 mg/dL | 0.74–1.66 g/L |
Adult | 83–200 mg/dL | 0.83–2 g/L |
Age | Conventional Units | SI Units (Conventional Units × 0.01) |
---|---|---|
Newborn | 10–31 mg/dL | 0.1–0.31 g/L |
6 mo–6 yr | 15–52 mg/dL | 0.15–0.52 g/L |
7–12 yr | 19–40 mg/dL | 0.19–0.4 g/L |
13–15 yr | 19–57 mg/dL | 0.19–0.57 g/L |
16–18 yr | 19–42 mg/dL | 0.19–0.42 g/L |
Adult | 12–36 mg/dL | 0.12–0.36 g/L |
Critical Findings and Potential Interventions
N/A
There's more to see -- the rest of this topic is available only to subscribers.